<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529932</url>
  </required_header>
  <id_info>
    <org_study_id>SELECT-AMI</org_study_id>
    <nct_id>NCT00529932</nct_id>
  </id_info>
  <brief_title>A Trial Using CD133 Enriched Bone Marrow Cells Following Primary Angioplasty for Acute Myocardial Infarction</brief_title>
  <acronym>SELECT-AMI</acronym>
  <official_title>A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Trial Using CD133 Enriched Bone Marrow Cells Following Primary Angioplasty for Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jozef Bartunek</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Onze Lieve Vrouw Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An international, multi-centre, double-blind, randomised, placebo-controlled clinical trial
      with central core lab analyses to determine the safety of intra-coronary infusion of enriched
      CD133+, bone marrow-derived, autologous progenitor cells in patients 5-10 days after acute
      percutaneous coronary revascularization (primary PCI) for ST-segment elevation myocardial
      infarction (STEMI).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient recruitment
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PRIMARY SAFETY ENDPOINT Comparison of progression in coronary atherosclerosis burden proximal and distal to the stented segment of the infarct-related artery in treated and control groups.</measure>
    <time_frame>at 6 months post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PRIMARY EFFICACY ENDPOINT Comparison of changes in myocardial thickening in non-viable akinetic / hypokinetic LV wall segments as determined by cardiac magnetic resonance imaging (cMRI) in treated and control groups.</measure>
    <time_frame>at 6 and 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SECONDARY SAFETY ENDPOINT (a) Development of ventricular arrhythmias including failed sudden cardiac death. (b) Development of congestive heart failure.</measure>
    <time_frame>At all follow up's</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SECONDARY EFFICACY ENDPOINTS (a) Changes in % global LV ejection fraction (EF) compared with baseline as determined by cMRI and echocardiography pre- and post-cell infusion subsequent to primary PCI.</measure>
    <time_frame>at all follow up's</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SECONDARY EFFICACY ENDPOINTS (b)Assessment of epicardial resistance and microvascular resistance, index of myocardial resistance and absolute coronary blood flow measurements in the infarct related artery.</measure>
    <time_frame>at 6 months follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SECONDARY EFFICACY ENDPOINTS (c) The feasibility of the CliniMACS® Reagent System to yield 5x106 CD133+ cells from 100-150 ml of autologous bone marrow.</measure>
    <time_frame>prior to the infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enriched CD133+, bone marrow-derived, autologous progenitor cells for this trial will be infused in the coronary arteries</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group patients will receive 3 injections of 0.3 mL each of buffered normal saline (the vehicle used for cell suspension) into comparable vessels. Subjects will have an identical intra-coronary injection procedure to those randomized to autologous CD133+ progenitor cell injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CD133+ infusion</intervention_name>
    <description>Subjects will be infused with all available autologous CD133+ cells after processing during one infusion session (during angiography).</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo infusion</intervention_name>
    <description>Buffered normal saline will be infused in the coronary artery during an angiography.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary PCI for acute STEMI between 2-24 hours after onset of chest pain.

          -  ST-segment elevation &gt;=2mm in &gt;=3 adjacent leads.

          -  Presence of severe hypokinesia and/or akinesia in &gt;=2 adjacent segments on
             echocardiogram at 48-72 hrs after primary PCI.

          -  Age between 20 and 75 years.

        Exclusion Criteria:

          -  Pregnant or lactating.

          -  Prior history of myocardial infarction before index event.

          -  Decompensated congestive heart failure.

          -  Pre-existent LV dysfunction (EF &lt;45% prior to admission)

          -  Cardiomyopathy.

          -  Previous cardiac surgery.

          -  Congenital heart disorder.

          -  Serum creatinine &gt;200 Mmol/L.

          -  Presence of permanent pacemaker or implantable defibrillator.

          -  Contraindication to bone marrow aspiration.

          -  History of malignancy within 5 years except curatively treated basal cell carcinoma,
             squamous cell carcinoma and/or cervical carcinoma.

          -  Sustained or inducible VT &gt;48 hours post primary PCI.

          -  Three vessel coronary artery disease necessitating intervention within 4 months.

          -  Immune compromise including chronic human immunodeficiency virus (HIV), hepatitis B
             virus (HBV) and hepatitis C virus (HCV) infection.

          -  Presence of chronic systemic inflammatory disorders.

          -  Previous autologous or allogeneic bone marrow or peripheral stem cell transplant or
             prior solid organ transplantation.

          -  Low hemoglobin, white blood cell, absolute neutrophil and/or platelet count.

          -  Any condition associated with a life expectancy of less than 6 months.

          -  Participation in unrelated research involving investigational pharmacological agent(s)
             30 days before planned dosing.

          -  Current alcohol or drug abuse.

          -  Inability to provide written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jozef Bartunek, MD</last_name>
    <role>Study Chair</role>
    <affiliation>OLVZ Aalst</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Hill, MD</last_name>
    <role>Study Chair</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OLVZ Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU ST-Pierre</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cardiologique</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College University Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2007</study_first_submitted>
  <study_first_submitted_qc>September 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Onze Lieve Vrouw Hospital</investigator_affiliation>
    <investigator_full_name>Jozef Bartunek</investigator_full_name>
    <investigator_title>Jozef Bartunek</investigator_title>
  </responsible_party>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>Celltherapy</keyword>
  <keyword>Bone Marrow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

